EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSRROG00000031252
Gene Symbol: MAP3K5
4 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSRROG00000044552
Gene Symbol: MAP3K8
4 Cross references
198 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSRROG00000021073
Gene Symbol: MAP3K9
4 Cross references
194 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Monoamine Oxidase A

Ensembl ID : ENSRROG00000039582
Gene Symbol: MAOA
2 Cross references
147 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Monoamine Oxidase B

Ensembl ID : ENSRROG00000041200
Gene Symbol: MAOB
4 Cross references
329 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Monoglyceride Lipase

Ensembl ID : ENSRROG00000042663
Gene Symbol: MGLL
4 Cross references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Motilin Receptor

Ensembl ID : ENSRROG00000044972
Gene Symbol: MLNR
4 Cross references
165 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Myeloperoxidase

Ensembl ID : ENSRROG00000001873
Gene Symbol: MPO
4 Cross references
181 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Natriuretic Peptide Receptor 1

Ensembl ID : ENSRROG00000033435
Gene Symbol: NPR1
4 Cross references
184 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Natriuretic Peptide Receptor 2

Ensembl ID : ENSRROG00000036014
Gene Symbol: NPR2
4 Cross references
259 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Natriuretic Peptide Receptor 3

Ensembl ID : ENSRROG00000037597
Gene Symbol: NPR3
4 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neuropeptide Y Receptor Y2

Ensembl ID : ENSRROG00000010670
Gene Symbol: NPY2R
4 Cross references
246 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).